Overview

This trial is active, not recruiting.

Condition prostate cancer
Treatments docetaxel, radiation therapy
Phase phase 1/phase 2
Sponsor OHSU Knight Cancer Institute
Start date January 2006
End date October 2009
Trial size 25 participants
Trial identifier NCT00321698, CDR0000467219, IIT16179, OHSU-1581, OHSU-SOL-05077-L, PVAMC-11-1205/ M1675

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This phase I/II trial is studying the side effects and best dose of docetaxel when given together with radiation therapy and to see how well they work in treating patients who are undergoing surgery for high-risk localized prostate cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model factorial assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Drug: docetaxel 4 groups of men in phase I study. Group 1=radiation only; Group 2=IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation Phase II with no phase I dose-limiting toxicities=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation Radiation: radiation therapy All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)
docetaxel
4 groups of men in phase I study. Group 1=radiation only; Group 2=IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation Phase II with no phase I dose-limiting toxicities=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation
radiation therapy
All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)

Primary Outcomes

Measure
Maximum tolerated dose
time frame: Between treatment groups
Pathologic response rate at the phase II dose
time frame: End of treatment

Secondary Outcomes

Measure
Prostate-specific antigen short-term response rate
time frame: Regular intervals
Long-term safety
time frame: Regular intervals
Clinical response to treatment as measured by urologic examination
time frame: Regular intervals
Surgical margin status at time of prostatectomy
time frame: End of treatment
Efficacy assessed using Health-Related Quality of Life by Expanded Prostate Cancer Index Composite and urinary symptom scores by American Urological Association's measures
time frame: Regular intervals
Clinical progression-free rate
time frame: Regular intervals
Response by assessing biologic markers in tissue and serum before treatment
time frame: Data analysis
Correlative serum biomarkers following study completion
time frame: Data analysis
Molecular impact by RNA content (gene expression profile) compared before and after treatment
time frame: Data analysis

Eligibility Criteria

Male participants at least 18 years old.

DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma of the prostate - Localized disease, meeting 1 of the following staging criteria: - Clinical stage T2b (palpable bilateral movement) disease - Surgically resectable T3 disease - Meets any of the following high-risk* features: - PSA ≥ 15 ng/mL - Gleason grade ≥ 4+3 (4+3, 4+4, or 5+any, but not 3+4) NOTE: *High risk defined as > 50% chance of failure with local therapy - Plans to undergo prostatectomy as primary therapy - No evidence of lymph nodes ≥ 2 cm in diameter by pelvic CT scan - Scan only required in patients with a PSA ≥ 40 ng/mL - No evidence of bone metastases by bone scan PATIENT CHARACTERISTICS: - Life expectancy ≥ 10 years - ECOG performance status 0-2 - WBC > 3,000/mm^3 - Neutrophil count > 1,500/mm^3 - Platelet count > 100,000/mm^3 - Direct bilirubin normal - ALT < 2.0 times upper limit of normal (ULN) (1.5 times ULN if alkaline phosphatase [AP] > 2.5 times ULN) - AP < 4.0 times ULN - No other serious medical condition that would preclude study treatment - No other malignancy within the past 5 years except nonmelanoma skin cancer - No peripheral neuropathy ≥ grade 2 - No hypersensitivity to drugs formulated with polysorbate 80 - No significant contraindications to corticosteroids - No history of scleroderma - No active inflammatory bowel disease (IBD) or IBD that is being medically treated - Inclusion of patients with a remote history of IBD is at the discretion of radiotherapist PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No prior therapy for prostate cancer, including any of the following: - Conventional hormonal therapy (e.g., orchiectomy, luteinizing hormone-releasing hormone therapy, antiandrogen therapy, or estrogen therapy) - External-beam radiotherapy or brachytherapy - Cryotherapy - Cytotoxic chemotherapy - No prior pelvic radiotherapy

Additional Information

Official title Phase I/II Study of Preoperative Radiation and Docetaxel Activity in High Risk Localized Prostate Cancer
Principal investigator Mark Garzotto, MD
Description OBJECTIVES: Primary - Determine the maximum tolerated dose (MTD) of neoadjuvant radiotherapy and docetaxel in patients who are undergoing prostatectomy for high-risk localized prostate cancer. - Determine the pathologic response rate in patients treated at the phase II dose. Secondary - Determine the prostate-specific antigen (PSA) short-term response rate in patients treated with this regimen. - Determine the long-term safety of this regimen prior to radical prostatectomy in these patients. - Determine the clinical response to this regimen by urologic examination of these patients. - Determine the surgical margin status at the time of prostatectomy in patients treated with this regimen. - Determine the effect of this regimen, in terms of Health-Related Quality of Life by Expanded Prostate Cancer Index Composite (EPIC) and urinary symptom scores by the American Urological Association's measures, in these patients. - Determine the clinical progression-free rate in patients treated with this regimen. - Identify pretreatment predictors of response in these patients by examining tissue biomarkers in preserved pretreatment biopsy specimens. - Determine the biologic impact of this regimen on these patients by examining the prostatectomy specimens. - Collect frozen serum for future analysis of correlative biomarkers. - Compare the RNA content (gene expression profile) of pre- and post-treatment tumor specimens in order to describe the molecular impact of this regimen on prostate cancer. OUTLINE: This is a phase I, dose-escalation study of docetaxel followed by a phase II study. All patients undergo a biopsy of the prostate to gather research-only specimens prior to the beginning of treatment. - Phase I: Patients undergo radiotherapy once daily, 5 days a week, for 5 weeks. Patients also receive docetaxel IV on days 1, 8, 15, 22, and 29. Treatment continues in the absence of disease progression or unacceptable toxicity. Approximately 4-6 weeks after completion of chemoradiotherapy, patients undergo a radical prostatectomy. Cohorts of 3-6 patients receive escalating doses of docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience a dose-limiting toxicity. At least 6 patients are treated at the MTD. - Phase II: Patients undergo radiotherapy as in phase I. Patients also receive docetaxel at the MTD determined in phase I and then undergo prostatectomy as in phase I. PROJECTED ACCRUAL: A total of 42 patients will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in April 2013.
Information provided to ClinicalTrials.gov by OHSU Knight Cancer Institute.